Canada markets closed

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
8.00-0.07 (-0.87%)
At close: 01:59PM EDT
Full screen
Previous Close8.07
Bid7.98 x 0
Ask8.08 x 0
Day's Range8.00 - 8.01
52 Week Range6.76 - 10.00
Avg. Volume4,442
Market Cap99.265M
Beta (5Y Monthly)0.89
PE Ratio (TTM)16.33
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BioSyent Releases Financial Results for Q1 2022

    MISSISSAUGA, Ontario, May 18, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2022. Key highlights include: First quarter (Q1) 2022 Net Revenues of $7,037,411 decreased by 5% versus Q1 2021Q1 2022 Net Revenues from continuing brands (excluding discontinued Aguettant System® and Cysview® brands) decreased by 0% versus Q1 2021Q1 2022 Canadian Pharmaceutical Net Revenues of $6,318,884 increased by 1% vers

  • GlobeNewswire

    BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022

    MISSISSAUGA, Ontario, May 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A presentation on the Company’s first quarter 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, B

  • GlobeNewswire

    FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year

    MISSISSAUGA, Ontario, May 02, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the seventh consecutive year, FeraMAX® is the #1 recommended iron supplement brand in Canada based on a national survey of Canadian pharmacists and physicians.1 This annual survey was conducted by EnsembleIQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHe